【レポートの概要（一部）】
1. Report Overview
1.1 Non-Small Cell Lung Cancer (NSCLC) Overview
1.2 Why You Should Read this Report
1.3 How this Report Delivers
1.4 Main Questions Answered by this Report
1.5 Who is this Report for?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQ)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to NSCLC and its Treatment
2.1 Lung Cancer is the Most Common Cancer, and NSCLC Accounts for 85%-90% of All Cases
2.2 The Three Main Histological Sub-Types of NSCLC
2.3 Genetic Mutations Allow for Targeted Therapies
2.4 Staging of NSCLC
2.5 Treatment Protocols by Stage
2.5.1 Stage 1 or 2
2.5.2 Stage 3
2.5.3 Stage 4: First Line-Therapy
2.5.3.1 Standard Chemotherapy Used to be the Only Treatment Option
2.5.3.2 Newer Therapies offers Improved Treatment Outcomes
2.5.3.3 Summary of First-Line Therapy Options: Un-Met Need in Squamous Patient Population
2.5.4 Maintenance Therapy
2.5.5 Second-Line and Third-Line Therapy
3. Leading NSCLC Drugs, 2015-2025
3.1 Alimta (pemetrexed) by Eli Lilly – The Leading NSCLC Therapy
3.1.1 Mechanism of Action
3.1.2 Three out of its Four FDA-Approved Indications are for NSCLC
3.1.3 Patent Expiries
3.1.3.1 ‘Method-Of-Use’ Vitamin Dosage Regimen Patent – Alimta’s Saviour from Generic Competition?
3.1.4 NICE Rejects Alimta for Maintenance Therapy
3.1.5 Total Alimta Revenues, 2010-2014
3.1.6 Alimta for NSCLC, 2014
3.1.7 Alimta for NSCLC Forecast, 2015-2025
3.2 Avastin (bevacizumab) – Roche’s Cancer Behemoth is a Leading Presence in NSCLC
3.2.1 Mechanism of Action
3.2.2 Multiple Approved Indications, but NSCLC was one of the First
3.2.3 Growing Discontent with Avastin in NSCLC – Is it Cost-Effective?
3.2.4 Total Avastin Revenues, 2010-2014
3.2.5 Avastin for NSCLC Forecast, 2015-2025
3.3 Tarceva (erlotinib) by Roche
3.3.1 Mechanism of Action
3.3.2 Three of Four Indications are for NSCLC
3.3.3 NICE Changes Mind on Tarceva – and then Changes it Back Again
3.3.4 Total Tarceva Revenues, 2010-2014
3.3.5 Tarceva for NSCLC Forecast, 2015-2025
3.4 Iressa (gefitinib) by AstraZeneca
3.4.1 Iressa Finally Returns to the Crucial US Market after Four Year Departure
3.4.2 Iressa NSCLC Revenues, 2010-2014
3.4.3 Iressa for NSCLC Forecast, 2015-2025
3.5 Gilotrif (afatinib) by Boehringer Ingelheim
3.5.1 Newcomer to the Market Rounds out the Trio of Currently Approved EGFR Inhibitors
3.5.2 Gilotrif Displays Significant Survival Benefit over Tarceva in Squamous Setting
3.5.3 Gilotrif for NSCLC Forecast, 2015-2025
3.6 Xalkori (crizotinib) by Pfizer
3.6.1 Mechanism of Action
3.6.2 The First Approved ALK Inhibitor
3.6.3 Co-Promotion with Merck KGaA, and has Treated Over 8,000 Patients
3.6.4 Xalkori NSCLC Revenues, 2012-2014
3.6.5 Xalkori for NSCLC Forecast, 2015-2025
3.7 Abraxane (paclitaxel Protein-Bound) by Celgene
3.7.1 Mechanism of Action
3.7.2 Relatively Recent Approval for NSCLC Indication
3.7.3 Finally Approved for NSCLC in the EU
3.7.4 Total Abraxane Revenues, 2010-2014
3.7.5 Abraxane for NSCLC Forecast, 2015-2025
3.8 Taxotere (docetaxel) by Sanofi
3.8.1 Mechanism of Action and Approved Indications
3.8.2 Sanofi Unable to Prevent Generics, Despite Appeal
3.8.3 Total Taxotere Revenues, 2010-2014
3.8.4 Taxotere for NSCLC Forecast, 2015-2025
3.9 Cyramza (ramucirumab) by Eli Lilly
3.9.1 Mechanism of Action
3.9.2 Many Approvals in Quick Succession
3.9.3 Cyramza for NSCLC Forecast, 2015-2025
3.10 Gemzar (gemcitabine) by Eli Lilly
3.11 Zykadia (ceritinib) by Novartis
3.11.1 Mechanism of Action and Recent Approval
3.11.2 Zykadia for NSCLC Forecast, 2015-2025
3.12 Opdivo (nivolumab) by Bristol-Myers Squibb
3.12.1 Mechanism of Action – Works With the Immune System to Fight Cancers
3.12.2 Swift Approvals through FDA Priority Review Programmes
3.12.3 Good News and Bad News for NSCLC from CheckMate Trials
3.12.4 Opdivo for NSCLC Forecast, 2015-2025
4. NSCLC R&D Pipeline, 2015-2025
4.1 Alecensa (alectinib) by Roche
4.1.1 Japan Becomes First Country to Approve and Launch Alectinib
4.1.2 Roche is Inching Closer Towards the All-Important US Approval
4.1.3 Four Ongoing Clinical Trials involving Alectinib in NSCLC
4.1.4 Japanese Revenues and Future Outlook
4.2 Vargatef (nintedanib) by Boehringer Ingelheim
4.2.1 EU Becomes First Region to Approve Vargatef
4.2.2 NICE has a Change of Heart on Vargatef
4.2.3 Ongoing Clinical Trials Involving Vargatef in NSCLC
4.3 AZD9291 by AstraZeneca
4.3.1 Regulatory Filings in the US and EU, Expected Times for Filings in Japan and China
4.3.2 Collaboration with Roche to Develop Companion Diagnostic
4.3.3 Positive Preliminary Results Presented at ASCO 2015
4.3.4 Ongoing Clinical Trials Involving AZD9291 in NSCLC
4.4 Rociletinib (CO-1686) by Clovis Oncology
4.4.1 In a Race to Approval Against AZD9291
4.4.2 Results So Far Have not Distinguished it Enough from Main Rival
4.4.3 Four Ongoing Clinical Trials Involving Rociletinib in NSCLC
4.5 Keytruda (pembrolizumab) by Merck (MSD)
4.5.1 Has Been Approved for Melanoma, NSCLC is one of the Next Major Targets
4.5.2 Ongoing Clinical Trials Involving Keytruda in NSCLC
4.6 Ganetespib (STA-9090) by Synta Pharmaceuticals
4.6.1 Ganetespib Mechanism of Action
4.6.2 Three Ongoing Clinical Trials Involving Ganetespib in NSCLC
4.7 Halaven (eribulin) by Eisai
4.7.1 Halaven Mechanism of Action
4.7.2 Clinical Trials Involving Halaven in NSCLC
4.8 Necitumumab by Eli Lilly
4.8.1 Phase 3 Results Show Modest Benefits and Worrying Adverse Event Profile
4.8.2 Eli Lilly has Filed for Approval in US and EU, and Verdict is Likely to be Positive, Despite Reservations
4.8.3 Ongoing Clinical Trials Involving Necitumumab in NSCLC
4.9 Atezolizumab (MPDL3280A) by Roche
4.9.1 Mechanism of Action
4.9.2 Atezolizumab Doubles Likelihood of Survival in Certain Subset of Patients
4.9.3 Six Ongoing Clinical Trials Involving Atezolizumab in NSCLC
5. Global NSCLC Market, 2015-2025
5.1 The Global NSCLC Market Forecast, 2015-2025
5.2 What Factors will Drive Growth in the Global NSCLC Market?
5.3 Growing Ageing Population
5.4 The Identification of Biomarkers for Targeted Therapies
5.5 Dynamic and Lucrative Sector with Strong Pipeline
5.6 Satisfying the Large Un-Met Need that is Treatment for Squamous Patients
5.7 What Factors will Restrain Growth in the Global NSCLC Market?
5.8 Patent Expiries and Generic Erosion will be the Main Detriment to the Market
5.9 New Therapies That Reportedly Offer Only Modest Benefits Over Existing Treatments
5.10 Declining Healthcare Budgets lead to Cost Pressures, and Resistance to Therapies is another Issue
5.11 SWOT Analysis of the Global NSCLC Market
6. Leading Therapeutic Segments and National Markets within the Global NSCLC Market
6.1 Therapeutic Composition of the Market in 2015 Compared to 2025
6.1.1 Therapeutic Segments Forecast, 2015-2025
6.1.2 Chemotherapy Segment Forecast, 2015-2025
6.1.3 EGFR and ALK Inhibitors Segment Forecast, 2015-2025
6.1.4 VEGF / VEGFR Inhibitors Segment Forecast, 2015-2025
6.1.5 Immunotherapy Segment Forecast, 2015-2025
6.2 Leading National Markets for NSCLC
6.2.1 Regional Composition of the Global Market in 2015, Compared to 2025
6.2.2 Leading Regional Markets for NSCLC Forecast, 2015-2025
6.2.3 US NSCLC Market, 2015-2025
6.2.3.1 Experiencing Some Changes, but Will Retain Dominance Throughout Forecast Period
6.2.3.2 US NSCLC Market Forecast, 2015-2025
6.2.4 EU5 NSCLC Market, 2015-2025
6.2.4.1 German NSCLC Market: Leader in EU, but Facing Big Reforms
6.2.4.2 German NSCLC Market Forecast, 2015-2025
6.2.4.3 French NSCLC Market: Strong National Healthcare System, Despite Economic Woes
6.2.4.4 French NSCLC Market Forecast, 2015-2025
6.2.4.5 Italian NSCLC Market
6.2.4.6 Italian NSCLC Market Forecast, 2015-2025
6.2.4.7 UK NSCLC Market: Pricing is a Key Issue, Providing Restraints to Revenues
6.2.4.8 UK NSCLC Market Forecast, 2015-2025
6.2.4.9 Spanish NSCLC Market
6.2.4.10 Spanish NSCLC Market Forecast, 2015-2025
6.2.5 Japanese NSCLC Market
6.2.5.1 Expansion of the Generics Market is a Key Factor
6.2.5.2 Japanese NSCLC Market Forecast, 2015-2025
6.2.6 BRIC NSCLC Market, 2015-2025
6.2.6.1 China NSCLC Market: Rapid Growth Will Make it one of the Major Global Players
6.2.6.2 China NSCLC Market Forecast, 2015-2025
6.2.6.3 Brazilian NSCLC Market: Taken Great Strides Forward with Healthcare
6.2.6.4 Brazilian NSCLC Market Forecast, 2015-2025
6.2.6.5 Russian NSCLC Market: Punches Below its Weight
6.2.6.6 Russian NSCLC Market Forecast, 2015-2025
6.2.6.7 Indian NSCLC Market: Generics are King
6.2.6.8 Indian NSCLC Market Forecast, 2015-2025
7. Research Interview
7.1 Interview with Novartis
7.1.1 On the Need for More than one ALK Inhibitor on the Market
7.1.2 Main Trends and Opportunities for NSCLC
7.1.3 The Present and the Future
8. Conclusions from Our Research and Analysis
8.1 How Will Revenues Change over the Forecast Period?
8.2 How will the Therapeutic Composition of the Market Change over the Forecast Period?
8.3 How Will the National Composition of the Global Market Change Over the Forecast Period?
8.4 Concluding Remarks
【レポート販売概要】
■ タイトル：非小細胞肺がん（NSCLC）治療薬の世界市場：市場、企業、研究開発展望■ 英文：Non-Small Cell Lung Cancer Drugs: Market, Companies and R&D Outlook 2015-2025
■ 発行日：2015年10月
■ 調査会社：visiongain
■ 商品コード：VGAIN5112511
■ 調査対象地域：グローバル
- 個人用保護具（PPE）の世界市場2015-2019About PPE Personal protective equipment, commonly referred to as PPE, are worn to minimize exposure to hazards. PPE may range from pads and gloves to masks and shields. PPE are used in a wide variety of industries, such as manufacturing, chemicals, construction, oil and gas, food, and pharmaceuticals. Apart from the workplace, PPE are also used in sports and other recreational activities to reduce …
- マイクロディスプレイの世界市場2016-2020About the Microdisplay Market Microdisplays are microminiaturized displays having a screen size of less than 25 millimeters (screen size refers to the diagonal distance from one corner to the opposite corner of the screen). They are high-density screens with high resolution and are used in magnified display systems. Microdisplays are often used in conjunction with magnifying optics because of thei …
- Liver Cirrhosis：グローバル臨床試験レビューH2, 2013Liver Cirrhosis Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, “Liver Cirrhosis Global Clinical Trials Review, H2, 2013" provides data on the Liver Cirrhosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Liver Cirrhosis. It includes an overview of the trial numbers and their recruitment status as …
- SemGroup, L.P.：石油・ガスバリューチェーン分析レポート2013SemGroup, L.P. Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "SemGroup, L.P." Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “SemGroup, L.P.”. The report provides key information relating to oil and gas assets of the company along with its operations across the value chain. The report examines the company’s …
- 世界の自動車ナイトビジョンシステム(NVS)市場2015The Global Automotive Night Vision Systems (NVS) Industry Report 2015 is a professional and in-depth study on the current state of the Automotive Night Vision Systems (NVS) industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Automotive Night Vision Systems (NVS) market analysis is provided for the inte …
- ロボット塗装ブースの世界市場2017-2021：塗装ブース、塗装ロボットAbout Robotic Paint Booth Almost every machine, ranging from a small component to an aircraft, requires a coat of paint over the metallic surface to protect it from corrosion. It is this need that makes manufacturers to adopt automated painting technologies in their facilities to ensure health safety of workers, improve throughput, and enhance process efficiency. Automated systems like paint robot …
- ポリブタジェン・ラバ(BR)の世界市場動向及び予測2015The present report is an essential resource for a one looking for detailed information on the world polybutadiene rubber market. The report covers data on global, regional and national markets including present and future trends for supply and demand, prices, and downstream industries. In addition to the analytical part, the report provides a range of tables and figures which all together give a t …
- 世界の空港IT市場動向（2012-2016）TechNavio's analysts forecast the Global Airport IT market to grow at a CAGR of 4.29 percent over the period 2012-2016. One of the key factors contributing to this market growth is the need to improve passenger experience. The Global Airport IT market has also been witnessing the increased demand for network virtualization. However, the high implementation cost of airport IT solutions could pose a …
- 水リサイクル及び再利用の世界市場2015-2019About Water Recycle and Reuse Water recycling is a process of reusing treated wastewater for useful purposes such as industrial processes, agricultural and landscape irrigation, domestic and commercial usage, and ground water recharge. Wastewater can be tailored to meet the requirements of specific planned application through the process of recycling. The production of recycled water is also refer …
- 小児てんかん治療薬の世界市場2019-2023107 pages, November 2018 About this market The emergence of biomarkers to gain traction in the market. The world of epilepsy diagnostics is experiencing a trend of emerging biomarkers for epileptogenesis. Epilepsy is the disorder of repeated seizures; hence, these biomarkers for epileptogenesis are used to identify the spontaneity of the seizures. Technavio’s analysts have predicted that the pedia …
- 石油・ガス市場の契約動向：Cameron LNG Award Drives Midstream SectorMonthly Oil & Gas Industry Contracts Review: Cameron LNG Award Drives Midstream Sector Summary GlobalData's “Monthly Oil & Gas Industry Contracts Review: Cameron LNG Award Drives Midstream Sector". The report is an essential source of data on the contracts and open tenders in the oil and gas industry. The report portrays detailed comparative data on the number of contracts and their value in the m …
- 支援ロボットの世界市場予測（～2024年）“Assistive robotics market expected to grow at a CAGR of 22.3% during 2019–2024” The assistive robotics market is expected to grow from USD 4.1 billion in 2019 to USD 11.2 billion by 2024, at a CAGR of 22.3% during the forecast period. One of the major driving factors for the assistive robotics market is the rising insurance coverage for medical exoskeletons and robotic surgeries. Also, the worldw …
- 溶融亜鉛メッキ鋼管のインド市場2017-2021ABSTRACTAbout Galvanized Steel Tubes The galvanized steel tubes market in India is primarily driven by the rapid industrialization, leading to increasing investments in building and construction activities in the country. The economy of India is growing at a significant rate, which is likely to impact the galvanized steel tubes market in the country. In India, the process industries, as well as th …
- RFID: Business Drivers, Business Case Analysis, and Business PlanFor many organizations, efficiency, ROI, manageability and performance is primarily dependent on the information retrieval process and the tracking of its products. Although many corporate giants have already implemented RFID Systems, RFID faces some challenges in terms of wide spread adoption. Business process automation provides a series of benefits including reduction of costs related to mainte …
- BRIC新興国の心臓補助処置動向（～2020）BRIC Cardiac Assist Procedures Outlook to 2020 Summary GlobalData’s new report, "BRIC Cardiac Assist Procedures Outlook to 2020", provides key procedures data on the BRIC Cardiac Assist Procedures. The report provides procedure volumes within market categories – Total Artificial Heart (TAH) Procedures and Ventricular Assist Procedures (Left Ventricular, Right Ventricular, External Ventricular and …
